Zevra Therapeutics, Inc. Cost of Revenue
Zevra Therapeutics, Inc. (ZVRA) reported Cost of Revenue of $10.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-28.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2020-02-28
- Zevra Therapeutics, Inc. cost of goods and services sold for the quarter ending 2019-12-31 was $9.00M.
- Zevra Therapeutics, Inc. cost of goods and services sold for the quarter ending 2019-09-30 was $1.00M.
- Zevra Therapeutics, Inc. cost of goods and services sold for fiscal 2019 was $10.00M.
- Zevra Therapeutics, Inc. cost of goods and services sold for fiscal 2018 was $0.00.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2019-12-31 | $9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $10.00M derived: sum of 2 quarters · filed 2020-02-28 | $10.00M 10-K · filed 2020-02-28 | |
| 2019-09-30 | $1.00M 10-Q · filed 2019-11-14 | $1.00M 10-Q · filed 2019-11-14 | ||
| 2018-12-31 | $0.00 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |